ALBERT BOURLA - 15 Dec 2022 Form 4 Insider Report for PFIZER INC (PFE)

Role: Chairman & CEO, Director
Signature: Susan E. Grant, by power of atty., for Albert Bourla
Issuer symbol: PFE
Transactions as of: 15 Dec 2022
Net transactions value: +$6,059,116
Form type: 4
Filing time: 16 Dec 2022, 17:14:34 UTC
Previous filing: 01 Dec 2022
Next filing: 03 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PFE	Common Stock	Options Exercise	$4,017,799	+133,172	+70%	$30.17	322,734	16 Dec 2022	Direct	F1
transaction	PFE	Common Stock	Options Exercise	$2,040,781	+89,156	+28%	$22.89	411,890	16 Dec 2022	Direct	F2
holding	PFE	Common Stock						4,146	15 Dec 2022	By Rule 16b-3 Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PFE	Phantom Stock Units SSP	Award	$536	+10	+0.01%	$53.61	96,391	15 Dec 2022	Common Stock	10		Direct	F3, F4
transaction	PFE	Stock Appreciation Rights	Options Exercise	$0	-285,161	-100%	$0.000000^*	0	16 Dec 2022	Common Stock	285,161	$30.17	Direct
transaction	PFE	Stock Appreciation Rights	Options Exercise	$0	-145,970	-100%	$0.000000^*	0	16 Dec 2022	Common Stock	145,970	$22.89	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the number of stock units received upon the exercise and conversion of previously granted stock appreciation rights (SARs), calculated by taking the change in Pfizer common stock price (20 trading day average ending on the exercise date (Election Price of $50.68)) less the grant price of the SAR plus accumulated dividends from the grant date, times the number of SARs exercised. This value is divided by the Election Price to determine the number of stock units. The stock units and accumulated dividend units will be settled in Pfizer common stock on the SAR original settlement date, the fifth anniversary of grant.
F2	Represents the number of stock units received upon the exercise and conversion of previously granted stock appreciation rights (SARs), calculated by taking the change in Pfizer common stock price (20 trading day average ending on the exercise date (Election Price of $50.68)) less the grant price of the SAR plus accumulated dividends from the grant date, times the number of SARs exercised. This value is divided by the Election Price to determine the number of stock units. The stock units and accumulated dividend units will be settled in Pfizer common stock on the SAR original settlement date, the seventh anniversary of grant.
F3	Each unit represents one phantom share of common stock.
F4	These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.